Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic LeukemiaJohn C. Byrd, Richard R. Furman, Bonnie K. Harrington et al.|New England Journal of Medicine|2015Cited by 890
Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphomaTalha Munir, Jennifer A. Woyach, Jennifer R. Brown et al.|American Journal of Hematology|2019Cited by 472
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 studyAnthony R. Mato, Michael Wang, David Lewis et al.|The Lancet|2021Cited by 456
Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trialJeffrey A. Jones, John C. Byrd, Anthony R. Mato et al.|The Lancet Oncology|2017Cited by 378
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic LeukemiaAnthony R. Mato, Wojciech Jurczak, Jennifer A. Woyach et al.|New England Journal of Medicine|2023Cited by 213